Chiesi gains commercialization rights to uniQure's Glybera

07/11/2013 | Pharmaceutical Business Review Online

Chiesi Farmaceutici secured exclusive rights to market uniQure's Glybera, the first gene therapy approved in Europe, for treatment of lipoprotein lipase deficiency. Chiesi and uniQure also agreed to jointly develop a hemophilia B gene therapy. UniQure will get 20% to 30% of net royalties on sales of both drugs.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA